Area riservata
Dislipidemia PPARs e sindome metabolica |
Scritto da Stagnaro Sergio | |||||||||
Pagina 5 di 6
10) Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607. 11) Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, 14) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 15) Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in 16) National Heart, Lung, and Blood Institute: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Bethesda, Md: National Cholesterol Education Program (NCEP), National Institutes of Health; 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm 17) Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 1999, 42:1033-1049. 18) Porte D Jr, Kahn SE: Beta- cell dysfunction and failure in type 2 diabetes: 19) Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, 20) Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 21) Vosper H, Khoudoli G, Graham T, Palmer C: Peroxisome proliferator-activated 22) Groop LC: Insulin resistance: the fundamental trigger of type 2 diabetes. Diab 26) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125, 1997. |